Literature DB >> 7534787

B cell antigen receptor-mediated apoptosis. Importance of accessory molecules CD19 and CD22, and of surface IgM cross-linking.

N Chaouchi1, A Vazquez, P Galanaud, C Leprince.   

Abstract

Engagement of the B cell Ag receptor can induce a suicide pathway in various B cell types. Earlier studies showed that anti-IgM mAb treatment triggers apoptotic death in the Burkitt lymphoma-derived cell line, Ramos. We show that two B cell surface molecules, CD19 and CD22, which have been reported to interact either functionally or structurally with the B cell Ag receptor, also stimulate cell suicide when sufficiently aggregated, both in the Ramos and EBV-infected Ramos AW cell lines. In conditions of lower cross-linking, both molecules enhance the apoptotic response induced by a suboptimal dose of anti-IgM mAb in Ramos cells, reinforcing the notion that CD19 and CD22 may be involved in the death pathway and modulate Ag-induced B cell apoptosis. Similar outcomes were obtained with human tonsillar B cells, which enter the death program upon treatment with cross-linked anti-IgM, -CD19, or -CD22 mAbs. These results indicate that Ag-induced B cell suicide may affect mature B cells in the periphery and may be regulated via the interaction of CD19 and/or CD22 with their respective ligand(s). Early tyrosine phosphorylations were analyzed by Western blotting. The biologic outcome of these various treatments--cell survival or death--could not be related to any detectable new tyrosine-phosphorylated substrate, further questioning the biochemical basis of apoptosis signaling.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7534787

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  23 in total

Review 1.  Positive and negative roles of CD72 in B cell function.

Authors:  Hsin-Jung Wu; Subbarao Bondada
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

2.  Anti-CD19 and anti-CD22 monoclonal antibodies increase the effectiveness of chemotherapy in Pre-B acute lymphoblastic leukemia cell lines.

Authors:  C Stanciu-Herrera; C Morgan; L Herrera
Journal:  Leuk Res       Date:  2007-08-15       Impact factor: 3.156

Review 3.  Investigational immunotherapeutics for B-cell malignancies.

Authors:  Alfonso Quintás-Cardama; William Wierda; Susan O'Brien
Journal:  J Clin Oncol       Date:  2010-01-04       Impact factor: 44.544

4.  Differential effects of BAFF on B cell precursor acute lymphoblastic leukemia and Burkitt lymphoma.

Authors:  Keiko Onda; Kazutoshi Iijima; Yohko U Katagiri; Hajime Okita; Masahiro Saito; Toshiaki Shimizu; Nobutaka Kiyokawa
Journal:  Int J Hematol       Date:  2010-04-29       Impact factor: 2.490

5.  CD22 EXON 12 deletion as a pathogenic mechanism of human B-precursor leukemia.

Authors:  Fatih M Uckun; Patricia Goodman; Hong Ma; Ilker Dibirdik; Sanjive Qazi
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-14       Impact factor: 11.205

Review 6.  The Sialoadhesins--a family of sialic acid-dependent cellular recognition molecules within the immunoglobulin superfamily.

Authors:  S Kelm; R Schauer; P R Crocker
Journal:  Glycoconj J       Date:  1996-12       Impact factor: 2.916

7.  Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis.

Authors:  B E Wilson; E Mochon; L M Boxer
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

8.  Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines.

Authors:  Rhona Stein; Mitchell R Smith; Susan Chen; Maria Zalath; David M Goldenberg
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

9.  An immunological renal disease in transgenic mice that overexpress Fli-1, a member of the ets family of transcription factor genes.

Authors:  L Zhang; A Eddy; Y T Teng; M Fritzler; M Kluppel; F Melet; A Bernstein
Journal:  Mol Cell Biol       Date:  1995-12       Impact factor: 4.272

10.  B-cell-activating factor inhibits CD20-mediated and B-cell receptor-mediated apoptosis in human B cells.

Authors:  Yohei Saito; Yoshitaka Miyagawa; Keiko Onda; Hideki Nakajima; Ban Sato; Yasuomi Horiuchi; Hajime Okita; Yohko U Katagiri; Masahiro Saito; Toshiaki Shimizu; Junichiro Fujimoto; Nobutaka Kiyokawa
Journal:  Immunology       Date:  2008-06-06       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.